Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.

Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM.

J Clin Pharmacol. 2014 Apr;54(4):468-77. doi: 10.1002/jcph.235. Epub 2013 Dec 11.

2.
3.

Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.

Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E.

J Opioid Manag. 2012 Sep-Oct;8(5):315-27. doi: 10.5055/jom.2012.0131.

PMID:
23247908
4.

Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.

Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC.

Clin Drug Investig. 2014 Jun;34(6):421-9. doi: 10.1007/s40261-014-0192-3.

5.

Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.

Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM.

J Opioid Manag. 2011 May-Jun;7(3):179-92.

PMID:
21823549
7.

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

Sellers EM, Perrino PJ, Colucci SV, Harris SC.

J Psychopharmacol. 2013 Sep;27(9):808-16. doi: 10.1177/0269881113493364. Epub 2013 Jun 19.

PMID:
23784739
8.

Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.

Webster LR, Bath B, Medve RA, Marmon T, Stoddard GJ.

Pain Med. 2012 Jun;13(6):790-801. doi: 10.1111/j.1526-4637.2012.01380.x. Epub 2012 May 8.

9.

Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.

Setnik B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, Geoffroy P.

J Clin Pharmacol. 2015 Dec;55(12):1351-61. doi: 10.1002/jcph.552. Epub 2015 Jul 2.

PMID:
26011742
10.

Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.

Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L.

Postgrad Med. 2014 Jul;126(4):20-32. doi: 10.3810/pgm.2014.07.2780.

PMID:
25141240
12.
13.

The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.

Setnik B, Roland CL, Cleveland JM, Webster L.

Pain Med. 2011 Apr;12(4):618-31. doi: 10.1111/j.1526-4637.2011.01093.x. Epub 2011 Apr 4.

14.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
15.

Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.

Kopecky EA, Fleming AB, Noonan PK, Varanasi RK, Grima M, Saim S, Mayock SP.

J Opioid Manag. 2014 Jul-Aug;10(4):233-46. doi: 10.5055/jom.2014.0211.

PMID:
25162603
16.

Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.

Gosai P, Ducharme MP, Godfrey AR, Freeman JC, Monif T, Kumar KS, Kumar S, Mudnaik R, Katikaneni P.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):895-907. doi: 10.5414/CP201764.

PMID:
23673291
17.

Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.

Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Barrett T, Young JL, Webster LR.

Postgrad Med. 2015 Jan;127(1):13-21. doi: 10.1080/00325481.2015.997395.

PMID:
25584931
18.
19.

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.

Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE.

Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3. Epub 2010 Apr 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk